Skip to content
HomeMedia CenterPress releases FinancialInvestor Conference Call Johnson & Johnson to Acquire Actelion for $30 Billion With Spin-Out of New R&D Company

Investor Conference Call Johnson & Johnson to Acquire Actelion for $30 Billion With Spin-Out of New R&D Company

Share Article
share to

New Brunswick, NJ (January 26, 2017) - Johnson & Johnson (NYSE: JNJ) and Actelion Ltd. (SIX: ATLN) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Thursday, Jan. 26th, to discuss the announcement that they have entered into a definitive agreement for Johnson & Johnson to acquire Actelion Ltd for $30 billion with a spin-out of a new R&D company.
The call will include the following participants:

Johnson & Johnson:
Alex Gorsky, Chairman and Chief Executive Officer
Dominic Caruso, Executive Vice President, Chief Financial Officer
Dr. Paul Stoffels, Chief Scientific Officer
Joaquin Duato, Executive Vice President, Worldwide Chairman, Pharmaceuticals Joseph J. Wolk, Vice President of Investor Relations

Jean-Pierre Garnier, Chairman
Dr. Jean-Paul Clozel, CEO and co-founder

Investors and other interested parties can access the webcast/conference call in the
following ways:

  • The webcast is accessible at Johnson & Johnson’s website: A webcast and podcast replay will be available approximately three hours after the conference call concludes.
  • By telephone: for both “listen-only” participants and those financial analysts who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-869-3847. For participants outside the U.S., the dial-in number is 201-689-8261.
  • A replay of the conference call will be available until approximately 12:00 a.m. on Feb. 3, 2017. The replay dial-in number for U.S. participants is 877-660-6853. For participants outside the U.S., the replay dial-in number is 201-612-7415. The replay conference ID number for all callers is 13654174 .
  • Presentation materials will be available on

About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,900 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

# # #

You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.